Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Byclot prophylaxis and prevention of hemophilic arthropathy progression in inhibitor patients
jRCT1031240268Recruiting
- Sponsor
- Hagiwara Tsuyoshi
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pd-FVIIa + FX in hemophilia A, hemophilia B (HB) and hemophilic arthropathy (HA), sponsored by Hagiwara Tsuyoshi. Primary endpoint: Change in Haemophilia Joint Health Score (HJHS). Started Jul 2024; status: recruiting.
02
Drugs
pd-FVIIa + FX
03
Conditions
hemophilia Ahemophilia B (HB)hemophilic arthropathy (HA)
Beyond the preview
Go deeper on jRCT1031240268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240268.